Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Schneider, D; Riegman, PH; Cronin, M; Negrouk, A; Moch, H; Balling, R; Penault-Llorca, F; Zatloukal, K; Horgan, D.
Accelerating the Development and Validation of New Value-Based Diagnostics by Leveraging Biobanks.
Public Health Genomics. 2016; 19(3):160-169
Doi: 10.1159/000446534
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Zatloukal Kurt
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The challenges faced in developing value-based diagnostics has resulted in few of these tests reaching the clinic, leaving many treatment modalities without matching diagnostics to select patients for particular therapies. Many patients receive therapies from which they are unlikely to benefit, resulting in worse outcomes and wasted health care resources. The paucity of value-based diagnostics is a result of the scientific challenges in developing predictive markers, specifically: (1) complex biology, (2) a limited research infrastructure supporting diagnostic development, and (3) the lack of incentives for diagnostic developers to invest the necessary resources. Better access to biospecimens can address some of these challenges. Methodologies developed to evaluate biomarkers from biospecimens archived from patients enrolled in randomized clinical trials offer the greatest opportunity to develop and validate high-value molecular diagnostics. An alternative opportunity is to access high-quality biospecimens collected from large public and private longitudinal observational cohorts such as the UK Biobank, the US Million Veteran Program, the UK 100,000 Genomes Project, or the French E3N cohort. Value-based diagnostics can be developed to work in a range of samples including blood, serum, plasma, urine, and tumour tissue, and better access to these high-quality biospecimens with clinical data can facilitate biomarker research. © 2016 S. Karger AG, Basel.
- Find related publications in this database (using NLM MeSH Indexing)
- Biological Specimen Banks -
- Humans -
- Informed Consent -
- Pathology, Molecular - standards
- Precision Medicine -
- Value-Based Purchasing -
- Find related publications in this database (Keywords)
- Archived sample
- Biobanks
- Biomarkers
- Biospecimen
- Informed consent
- Liquid biopsy
- Molecular diagnostics
- Next-generation sequencing
- Personalized medicine